

To: 5.1.2e @pfrizer.com]; 5.1.2e @pfrizer.com];
5.1.2e @ec.europa.eu]; 5.1.2e @ec.europa.eu]; 5.1.2e @ec.europa.eu]; 5.1.2e @ec.europa.eu];
5.1.2e @health.fgov.be]; 5.1.2e @health.fgov.be];
5.1.2e @commissariat.fed.be]; 5.1.2e @commissariat.fed.be]; 5.1.2e @fagg-afmps.be]; 5.1.2e @fagg-afmps.be];
5.1.2e @dgtresor.gouv.fr]; 5.1.2e @dgtresor.gouv.fr];
5.1.2e @igf.finances.gouv.fr]; 5.1.2e @igf.finances.gouv.fr]; 5.1.2e @bmg.bund.de]; 5.1.2e @bmg.bund.de];
5.1.2e @bmg.bund.de]; 5.1.2e @bmg.bund.de]; 5.1.2e @bmg.bund.de]; 5.1.2e @bmg.bund.de]; 5.1.2e @bmg.bund.de];
5.1.2e @hse.ie]; 5.1.2e @hse.ie]; 5.1.2e @health.gov.ie]; 5.1.2e @health.gov.ie];
5.1.2e @sanita.it]; 5.1.2e @sanita.it]; 5.1.2e @covid19.difesa.it]; 5.1.2e @covid19.difesa.it];
5.1.2e @covid19.difesa.it]; 5.1.2e @covid19.difesa.it]; 5.1.2e @ms.etat.lu]; 5.1.2e @ms.etat.lu];
5.1.2e @ms.etat.lu]; 5.1.2e @ms.etat.lu]; 5.1.2e @minvws.nl]; 5.1.2e @minvws.nl];
5.1.2e @minbuza.nl]; 5.1.2e @minbuza.nl]; 5.1.2e @infarmed.pt]; 5.1.2e @infarmed.pt];
5.1.2e @infarmed.pt]; 5.1.2e @infarmed.pt]; 5.1.2e @aemps.es]; 5.1.2e @aemps.es];
5.1.2e @pfrizer.com]; 5.1.2e @pfrizer.com]; 5.1.2e @pfrizer.com]; 5.1.2e @pfrizer.com];
5.1.2e @santepubliquefrance.fr]; 5.1.2e @santepubliquefrance.fr];
5.1.2e @diplomatie.gouv.fr]; 5.1.2e @diplomatie.gouv.fr];
5.1.2e @diplomatie.gouv.fr]; 5.1.2e @diplomatie.gouv.fr];
5.1.2e @santepubliquefrance.fr]; 5.1.2e @santepubliquefrance.fr];

Cc: 5.1.2e [REDACTED]@PFIZER.COM[REDACTED] 5.1.2e [REDACTED]@PFIZER.COM[REDACTED]
5.1.2e [REDACTED]@ec.europa.eu[REDACTED] 5.1.2e [REDACTED]@ec.europa.eu[REDACTED] 5.1.2e [REDACTED]@ext.ec.europa.eu[REDACTED] 5.1.2e [REDACTED]@ext.ec.europa.eu[REDACTED]; 5.1.2e [REDACTED]@ec.europa.eu[REDACTED] 5.1.2e [REDACTED]@ec.europa.eu[REDACTED]; 5.1.2e [REDACTED]@ec.europa.eu[REDACTED] 5.1.2e [REDACTED]@ec.europa.eu[REDACTED]; 5.1.2e [REDACTED]@ec.europa.eu[REDACTED] 5.1.2e [REDACTED]@ec.europa.eu[REDACTED]; 5.1.2e [REDACTED]@ec.europa.eu[REDACTED] 5.1.2e [REDACTED]@ec.europa.eu[REDACTED]; 5.1.2e [REDACTED]@ec.europa.eu[REDACTED] 5.1.2e [REDACTED]@ec.europa.eu[REDACTED]; 5.1.2e [REDACTED]@mfa.no[REDACTED] 5.1.2e [REDACTED]@mfa.no[REDACTED] 5.1.2e [REDACTED]@gov.se[REDACTED] 5.1.2e [REDACTED]@gov.se[REDACTED]; 5.1.2e [REDACTED]@Pfizer.com[REDACTED] 5.1.2e [REDACTED]@Pfizer.com[REDACTED] 5.1.2e [REDACTED]@pfizer.com[REDACTED] 5.1.2e [REDACTED]@pfizer.com[REDACTED]; 5.1.2e [REDACTED]@pfizer.com[REDACTED] 5.1.2e [REDACTED]@pfizer.com[REDACTED] 5.1.2e [REDACTED]@pfizer.com[REDACTED] 5.1.2e [REDACTED]@pfizer.com[REDACTED]; 5.1.2e [REDACTED]@pfizer.com[REDACTED] 5.1.2e [REDACTED]@pfizer.com[REDACTED] 5.1.2e [REDACTED]@Pfizer.com[REDACTED] 5.1.2e [REDACTED]@Pfizer.com[REDACTED]; 5.1.2e [REDACTED]@pfizer.com[REDACTED] 5.1.2e [REDACTED]@pfizer.com[REDACTED] 5.1.2e [REDACTED]@pfizer.com[REDACTED] 5.1.2e [REDACTED]@pfizer.com[REDACTED]

From: 5.1.2e @aemps.es

Sent: Tue 10/26/2021 5:53:39 PM

Subject: RE: URGENT_[CONFIDENTIAL] BioNTech-Pfizer - Pausing of Doses - Q42021 - Breakdown donations to COVAX vs. bilateral donations/resell

Received: Tue 10/26/2021 5:53:47 PM

Dear 5.1.2e
Dear colleagues,

Just to let you know that for the Spanish November doses we are still waiting for the COVAX acceptance. They sent us an e-mail earlier this morning acknowledging the receipt and saying that they are working closely with Pfizer on overcoming the challenges.

We will send a new mandate to France for the December doses tomorrow at the latest (4.001.400 doses)

Best regards,

5.1.2e

Departamento de Medicamentos de Uso Humano/Department of Medicines for Human Use
Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)
 Calle Campezo 1 • Edificio 8 • E-28022 Madrid • España/Spain

CONFIDENCIALIDAD. El contenido de este mensaje y el de cualquier documentación anexa es confidencial y va dirigido únicamente al destinatario del mismo. Si Usted no es el destinatario, le solicitamos que nos lo indique, no comunique su contenido a terceros y proceda a su destrucción.

CONFIDENTIALITY. The content of this message and any attached information is confidential and exclusively for the use of the addressee. If you are not the addressee, we ask you to notify to the sender, do not pass its content and delete the original.

De: 5.1.2e <5.1.2e@pfizer.com>

Enviado el: martes, 26 de octubre de 2021 19:05

Para: 5.1.2e < 5.1.2e @ec.europa.eu>; 5.1.2e @ec.europa.eu; 5.1.2e
< 5.1.2e @health.fgov.be>; 5.1.2e @commissariat.fed.be < 5.1.2e @commissariat.fed.be>;
5.1.2e @fagg-afmps.be < 5.1.2e @fagg-afmps.be>; 5.1.2e @dgtresor.gouv.fr < 5.1.2e @dgtresor.gouv.fr>;
5.1.2e @igf.finances.gouv.fr; COVID-19-vaccines < 5.1.2e @bmg.bund.de>; 5.1.2e @bmg.bund.de < 5.1.2e @bmg.bund.de>;

Importancia: Alta

Dear 5.1.2e

Dear All,

BR,

Pfizer Bldg. Dubai Media City, Dubai, UAE
P.O. Box 502749
5.1.2e 5.1.2e
5.1.2e @pfizer.com



Sent: Tuesday, October 26, 2021 8:40 PM

To: 5.1.2e <5.1.2e@ec.europa.eu>; 5.1.2e @ec.europa.eu' <5.1.2e@ec.europa.eu>; 5.1.2e <5.1.2e@health.fgov.be>; 5.1.2e @commissariat.fed.be' <5.1.2e@commissariat.fed.be>; 5.1.2e @fagg-afmps.be' <5.1.2e@fagg-afmps.be>; 5.1.2e @dgtresor.gouv.fr' <5.1.2e@dgtresor.gouv.fr>; 5.1.2e @igf.finances.gouv.fr' <5.1.2e@igf.finances.gouv.fr>; 5.1.2f Functionele emailadressen <5.1.2e <5.1.2e@bmg.bund.de>; 5.1.2e @bmg.bund.de' <5.1.2e@bmg.bund.de>; 5.1.2e <5.1.2e@bmg.bund.de>; 5.1.2e <5.1.2e@bmg.bund.de>; 5.1.2e @hse.ie' <5.1.2e@hse.ie>; 5.1.2e @health.gov.ie' <5.1.2e@health.gov.ie>; 5.1.2e @sanita.it'

< 5.1.2e @sanita.it>; 5.1.2e < 5.1.2e @covid19.difesa.it>; 5.1.2e
 < 5.1.2e @covid19.difesa.it>; 5.1.2e @ms.etat.lu' < 5.1.2e @ms.etat.lu>; 5.1.2e @ms.etat.lu'
 < 5.1.2e @ms.etat.lu>; 5.1.2e < 5.1.2e @minvws.nl>; 5.1.2e @minbuza.nl'
 < 5.1.2e @minbuza.nl>; 5.1.2e @infarmed.pt' < 5.1.2e @infarmed.pt>; 5.1.2e < 5.1.2e @infarmed.pt>;
 5.1.2e @aemps.es' < 5.1.2e @aemps.es>; 5.1.2e @aemps.es' < 5.1.2e @aemps.es>; 5.1.2e
 < 5.1.2e @pfizer.com>; 5.1.2e @pfizer.com>; 5.1.2e
 < 5.1.2e @santepubliquefrance.fr>; 5.1.2e @diplomatie.gouv.fr>; 5.1.2e
 < 5.1.2e @diplomatie.gouv.fr>; 5.1.2e @santepubliquefrance.fr
 Cc: 5.1.2e < 5.1.2e @PFIZER.COM>; 5.1.2e @ec.europa.eu>; 5.1.2e
 5.1.2e < 5.1.2e @ext.ec.europa.eu>; 5.1.2e < 5.1.2e @ec.europa.eu>; 5.1.2e
 5.1.2e @ec.europa.eu>; 5.1.2e @ec.europa.eu>; 5.1.2e
 5.1.2e @mfa.no>; 5.1.2e @gov.se' < 5.1.2e @gov.se>; 5.1.2e
 < 5.1.2e @Pfizer.com> 5.1.2e @pfizer.com> 5.1.2e @pfizer.com> 5.1.2e
 < 5.1.2e @pfizer.com>; 5.1.2e @pfizer.com> 5.1.2e @pfizer.com>;
 < 5.1.2e @pfizer.com> 5.1.2e @Pfizer.com> 5.1.2e
 < 5.1.2e @pfizer.com>

Subject: URGENT_[CONFIDENTIAL] BioNTech-Pfizer - Pausing of Doses - Q4 2021 - Breakdown donations to COVAX vs. bilateral donations/resell

Importance: High

Privileged and Confidential

Dear France and Esteemed Member States Representatives,

We are still missing important information, we appreciate your **swift and urgent** action:

- **Locking our supply plans** – we have locked our supply plans for both October and November doses, based on the attached final overview (please refer to the first and second sheet). Unfortunately, no further requests will be accepted for October and November paused doses (i.e. columns F & L for each sheet cannot be updated).
- **Offer Notice Acceptance Date by GAVI/COVAX** – We are still missing the acceptance of GAVI/COVAX for some markets (highlighted in red): (1) Portugal (2) Ireland (3) Spain (4) The Netherlands (5) Luxembourg (6) Norway. Please note GAVI/COVAX has 10 business days to accept the offer notices as per the tripartite agreement with France/Pfizer. If requests are not explicitly accepted by GAVI/COVAX, that means the process has not actually been kicked-off. Kindly urge you to reach out and follow up closely with GAVI/COVAX on their swift acceptance within the 10 business days.
- **Allocation of Gavi Shared Doses & Shipment Requests/PO issuance** – We only received few POs so far (my understanding two POs for Rwanda and Bolivia). GAVI will be scheduling a tripartite call this week to discuss the end-to-end donations process and the current hurdles for donations. Please follow up with 5.1.2e & the EC team if you wish to attend.
- **New proposal to facilitate donations** – For the required side letters, we are waiting for some feedback from GAVI/COVAX (being party to France Tripartite Agreement). Once received, the final side letters will be shortly shared by Pfizer to Team Europe/ 5.1.2e and then to France/relevant Member States.
- **Future Donations** – Any future donations for **ALL Member States** should come from December allocation onwards (which is now open under the standard ordering process). Please reach out to Pfizer local team or myself if you have any questions regarding December donations.

Should you have any inquiries, please do not hesitate to contact me.

BR,

5.1.2e

Pfizer Bldg. Dubai Media City, Dubai, UAE

P.O. Box 502749



5.1.2e



5.1.2e



5.1.2e

[@pfizer.com](mailto:5.1.2e@pfizer.com)

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

Dul

5 - 11

Dubbel